Assay Prediction Pathology Clinical Features
Tissue of Origin Veridex Histology IHC Age/Sex Sites of Metastasis Intra-abdominal Location (Y/N) Response to Treatment Survival (mo)
Colorectal Colon Adenocarcinoma CK20+, CK7-, TTF1-, CEA- 73/F Pleura, left adrenal Y SD 23
Colorectal Other Adenocarcinoma None 64/F Liver, omentum, peritoneum, pancreas Y UE 1
Colorectal Pancreas Adenocarcinoma CK7+, CK20-, CA125-, TTF1-, CEA- 66/F Liver Y UE 4
Colorectal NSCLC PD adenocarcinoma CK+, CK20+, PLAP-, PSA/PSAP-, melanin A- 71/M Abdomen, Soft tissue Y SD 21
Pancreas Colon Adenocarcinoma None 44/F Liver, abdominal wall, peritoneum Y UE 1
Kidney Colon PD carcinoma CK+, calretinin+, vimentin+, chromogranin-, CD15-, CD10-, AFP-, CEA- 64/M Liver, peritoneum Y SD 6
NSCLC Colon Squamous None 59/M Lymph nodes, internal jugular vein mass N PD 7
                 
Ovary Ovary PD carcinoma CK7+, ER+, PR+, GCDFP15-, HER2- 69/F Lung, liver, lymph nodes, pelvis, abdomen Y PR 57
Ovary Ovary PD carcinoma AE1/AE3+, CK7+, EMA+, CK5/6+, calretinin+, pan keratin+, CEA-, CK20-, LeuM1-, thyroglobulin-, ER-, PR-, Her2/neu-, HMB45-, S100-,chromogranin-, synaptophysin-, NSE- 45/F Lung, bone, pelvis, lymph nodes, mediastinum Y SD 6
Ovary Other Adenocarcinoma CK7+, CD15+, CEA+, calretinin-, CK20-, GCDFP15-, S100-, TTF1- 70/F Lung N PR 19
Ovary Other PD adenocarcinoma None 48/F Lung, liver, mediastinum Y SD 18
Ovary NSCLC PD adenocarcinoma CK+, CK7+, CEA+, ER-, PR-, HER2-, CK20-, HMB45-, S100- 51/F Lung, liver Y PD 5
Sarcoma Ovary PD carcinoma vimentin+, NSE+, CD117+, synaptophysin+, S100-, HMB45-, LCA-, chromogranin-, actin-, desmin-, pan CK-, EMA- 40/F Lung, liver, pelvis Y PD 9
Table 4: Clinicopathologic Characteristics of Patients with Colorectal (n = 7) or Ovary (n = 6) Prediction.